Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

Genetics of biliary tract cancers and emerging targeted therapies.

Hezel AF, Deshpande V, Zhu AX.

J Clin Oncol. 2010 Jul 20;28(21):3531-40. doi: 10.1200/JCO.2009.27.4787. Epub 2010 Jun 14. Review.

2.

Development of molecularly targeted therapies in biliary tract cancers: reassessing the challenges and opportunities.

Zhu AX, Hezel AF.

Hepatology. 2011 Feb;53(2):695-704. doi: 10.1002/hep.24145. Review.

PMID:
21274890
3.

Phase II trial of erlotinib and docetaxel in advanced and refractory hepatocellular and biliary cancers: Hoosier Oncology Group GI06-101.

Chiorean EG, Ramasubbaiah R, Yu M, Picus J, Bufill JA, Tong Y, Coleman N, Johnston EL, Currie C, Loehrer PJ.

Oncologist. 2012;17(1):13. doi: 10.1634/theoncologist.2011-0253. Epub 2011 Dec 30.

4.

Clinicopathological and prognostic significances of EGFR, KRAS and BRAF mutations in biliary tract carcinomas in Taiwan.

Chang YT, Chang MC, Huang KW, Tung CC, Hsu C, Wong JM.

J Gastroenterol Hepatol. 2014 May;29(5):1119-25. doi: 10.1111/jgh.12505.

PMID:
24372748
5.

Molecular Targets in Biliary Carcinogenesis and Implications for Therapy.

Oyasiji T, Zhang J, Kuvshinoff B, Iyer R, Hochwald SN.

Oncologist. 2015 Jul;20(7):742-51. doi: 10.1634/theoncologist.2014-0442. Epub 2015 May 29. Review.

6.

Targeted therapy for biliary tract cancers.

Faris JE, Zhu AX.

J Hepatobiliary Pancreat Sci. 2012 Jul;19(4):326-36. doi: 10.1007/s00534-011-0496-0. Review.

PMID:
22318523
7.

New genomic landscapes and therapeutic targets for biliary tract cancers.

Simbolo M, Fassan M, Mafficini A, Lawlor RT, Ruzzenente A, Scarpa A.

Front Biosci (Landmark Ed). 2016 Jan 1;21:707-18. Review.

PMID:
26709801
8.

Matching genomic molecular aberrations with molecular targeted agents: Are biliary tract cancers an ideal playground?

Verlingue L, Hollebecque A, Boige V, Ducreux M, Malka D, Ferté C.

Eur J Cancer. 2017 Aug;81:161-173. doi: 10.1016/j.ejca.2017.05.006. Epub 2017 Jun 17. Review.

PMID:
28628842
9.

Immunotherapy of biliary tract cancer.

Chai Y.

Tumour Biol. 2016 Mar;37(3):2817-21. doi: 10.1007/s13277-015-4743-x. Epub 2016 Jan 4. Review.

PMID:
26729196
10.

The V599E BRAF mutation is uncommon in biliary tract cancers.

Goldenberg D, Rosenbaum E, Argani P, Wistuba II, Sidransky D, Thuluvath PJ, Hidalgo M, Califano J, Maitra A.

Mod Pathol. 2004 Nov;17(11):1386-91.

11.

Cellular and molecular biology of biliary tract cancers.

Rashid A.

Surg Oncol Clin N Am. 2002 Oct;11(4):995-1009. Review.

PMID:
12607585
12.

Cetuximab, gemcitabine and capecitabine in patients with inoperable biliary tract cancer: a phase 2 study.

Rubovszky G, Láng I, Ganofszky E, Horváth Z, Juhos E, Nagy T, Szabó E, Szentirmay Z, Budai B, Hitre E.

Eur J Cancer. 2013 Dec;49(18):3806-12. doi: 10.1016/j.ejca.2013.07.143. Epub 2013 Sep 2.

PMID:
24007821
13.

Biliary tract carcinomas: from chemotherapy to targeted therapy.

Marino D, Leone F, Cavalloni G, Cagnazzo C, Aglietta M.

Crit Rev Oncol Hematol. 2013 Feb;85(2):136-48. doi: 10.1016/j.critrevonc.2012.06.006. Epub 2012 Jul 17. Review.

PMID:
22809696
14.

Mutational profiling reveals PIK3CA mutations in gallbladder carcinoma.

Deshpande V, Nduaguba A, Zimmerman SM, Kehoe SM, Macconaill LE, Lauwers GY, Ferrone C, Bardeesy N, Zhu AX, Hezel AF.

BMC Cancer. 2011 Feb 8;11:60. doi: 10.1186/1471-2407-11-60.

15.

Genomic Profiling of Biliary Tract Cancers and Implications for Clinical Practice.

Jain A, Kwong LN, Javle M.

Curr Treat Options Oncol. 2016 Nov;17(11):58. Review.

PMID:
27658789
16.

Targeted therapy in biliary tract cancer: 2009 update.

Tonini G, Virzì V, Fratto ME, Vincenzi B, Santini D.

Future Oncol. 2009 Dec;5(10):1675-84. doi: 10.2217/fon.09.130. Review.

PMID:
20001803
17.

Targeting EGFR/HER2 pathways enhances the antiproliferative effect of gemcitabine in biliary tract and gallbladder carcinomas.

Pignochino Y, Sarotto I, Peraldo-Neia C, Penachioni JY, Cavalloni G, Migliardi G, Casorzo L, Chiorino G, Risio M, Bardelli A, Aglietta M, Leone F.

BMC Cancer. 2010 Nov 18;10:631. doi: 10.1186/1471-2407-10-631.

18.

State-of-the-art in the management of locally advanced and metastatic gallbladder cancer.

McNamara MG, Metran-Nascente C, Knox JJ.

Curr Opin Oncol. 2013 Jul;25(4):425-31. doi: 10.1097/CCO.0b013e3283620fd8. Review.

PMID:
23635800
19.

A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response.

Chen Z, Cheng K, Walton Z, Wang Y, Ebi H, Shimamura T, Liu Y, Tupper T, Ouyang J, Li J, Gao P, Woo MS, Xu C, Yanagita M, Altabef A, Wang S, Lee C, Nakada Y, Peña CG, Sun Y, Franchetti Y, Yao C, Saur A, Cameron MD, Nishino M, Hayes DN, Wilkerson MD, Roberts PJ, Lee CB, Bardeesy N, Butaney M, Chirieac LR, Costa DB, Jackman D, Sharpless NE, Castrillon DH, Demetri GD, Jänne PA, Pandolfi PP, Cantley LC, Kung AL, Engelman JA, Wong KK.

Nature. 2012 Mar 18;483(7391):613-7. doi: 10.1038/nature10937.

20.

Ki-ras point mutations and proliferation activity in biliary tract carcinomas.

Ohashi K, Tstsumi M, Nakajima Y, Nakano H, Konishi Y.

Br J Cancer. 1996 Sep;74(6):930-5.

Supplemental Content

Support Center